Zhou et al. demonstrated that the IGF-1R kinase inhibitor nVp-ADW742 combined with temozolomide could trigger inhibition of P38, GSK3β, and AKT phosphorylation along with a considerable reduction in the intracellular expression levels of Bcl-2, P38, and GSK3β, thereby resulting in promoting response to chemotherapeutic drug temozolomide in medulloblastoma to a large extent (Zhou et al., 2011). This evidence concerns the gene GSK3B and medulloblastoma.